ArticlePsychiatry and clinical psychopharmacology2025
The Effects of Cinepazide Maleate in Conjunction with Edaravone on Cerebral Blood Flow and Neurofunctional Parameters in Individuals with Acute Ischemic Stroke.
Article in Psychiatry and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This research is focused on evaluating the influence of administering cinepazide maleate and edaravone together on cerebral blood flow and neurofunctional markers in individuals who have recently suffered from an acute ischemic stroke (AIS). Methods: Included in this retrospective investigation were 100 patients diagnosed with AIS and treated at our medical center between the period of December 2022 and December 2023. These individuals were subsequently segregated into 2 cohorts according to the different treatments they received, consisting of 50 patients each, referred to as the control group and the observation group. Upon admission, standard treatment was initiated for all patients, alongside additional edaravone therapy for the control group, and concurrent administration of cinepazide maleate and edaravone for the observation group, for a consecutive period of 14 days. The study involved the assessment of cerebral blood flow in the middle cerebral artery (MCA) and anterior cerebral artery (ACA), in addition to the evaluation of neurofunctional markers, serum inflammatory factors, activities of daily living (ADL) scores, and National Institutes of Health Stroke Scale (NIHSS) scores. Adverse reactions were closely monitored to determine the treatment's efficacy. Results: Subsequent to the treatment, augmented blood flow velocities were observed in both the MCA and ACA for both groups, particularly evident in the observation group. The observation group also demonstrated raised levels of nerve growth factor and lower levels of neuron-specific enolase and S100-β, with more notable differences when contrasted with the control group. Additionally, the observation group displayed reduced levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1, and elevated levels of interleukin-10 (IL-10), with more substantial variations as opposed to the control group. Furthermore, the observation group indicated enhanced ADL scores and diminished NIHSS scores, with more notable differences compared to the control group. The overall treatment effectiveness reached 94.00% in the observation group, markedly surpassing the 74.00% achieved in the control group. Conclusion: The concurrent application of cinepazide maleate and edaravone yields notable effects on cerebral blood flow and contributes to the improvement of neurofunctional capabilities in individuals dealing with AIS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.